8月23日，药明生物2021年上半年营收44.1亿元，去年同期19.44亿元；上半年净利润18.4亿元，去年同期7.36亿元；上半年每股盈利0.42元，去年同期0.18元；上半年毛利率52.1%，去年同期为40.5%。
报告期内，集团再次超额完成业绩目标。凭藉其行业领先的赋能平台，集团继续成功实施“赢得分子”策略，为加速及转变生物药(特别是COVID-19药物及疫苗)的发现、开发及生产提供端到端解决方案。
根据披露，综合项目数由去年同期的286个，增长42.7%至2021年6月30日的408个；临床前项目数由去年同期的141个，增长50.4%至2021年6月30日的212个；早期(第I及II期)临床开发项目数由去年同期的125个，增长28.0%至2021年6月30日的160个(其中I期项目116个、II期项目44个)；后期(第III期)临床开发项目数由去年同期的19个，增长68.4%至2021年6月30日的32个，为启动更多的商业化生产项目奠定基础；集团在报告期内新增两个商业化生产项目；集团成功将更多项目从IND前阶段进展至IND后阶段：报告期内，14个项目已由临床前开发阶段进入早期临床开发阶段。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments